Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto M R, Gianotti L, Ghigo E, Chiumello G
Paediatric Department, University of Milan, Italy.
Dement Geriatr Cogn Disord. 1998 Mar-Apr;9(2):78-81. doi: 10.1159/000017027.
There are data indicating that cholinergic activity is precociously impaired in Down's syndrome (DS). On the other hand, acetylcholine as well as arginine (ARG) play a major stimulatory role in the neural control of growth hormone (GH) secretion in humans, likely acting via the inhibition of hypothalamic somatostatin release. The aim of the present study was to verify the effects of pyridostigmine (PD, 120 mg p.o.), a cholinesterase inhibitor, and ARG (0.5 g/kg i.v.) on the growth hormone-releasing hormone (GHRH) (1 microgram/kg i.v.)-induced GH rise in 15 adult patients with DS (M/F: 8/7; age 26.5 +/- 2.2 years; body mass index, BMI: 25.7 +/- 1.0 kg/m2) in which the potentiating effect of PD on GH secretion has been reported to be reduced. The results in DS were compared to those in 15 normal subjects (NS) (M/F: 8/7; age: 30.0 +/- 1.3 years; BMI: 21.4 +/- 0.4 kg/m2). Basal GH and insulin growth factor I (IGF-1) levels in DS (1.8 +/- 0.7 and 206.5 +/- 21.0 micrograms/l) were similar to those in NS (1.4 +/- 0.3 and 179.4 +/- 11.0 micrograms/l). The GH response to GHRH alone in DS (526.5 +/- 120.1 micrograms/l/h) was lower (p < 0.05) than that recorded in NS (895.4 +/- 153.7 micrograms/l/h). The GHRH-induced GH rise was potentiated by PD both in DS (1,138 +/- 184.2 micrograms/l/h; p < 0.02 vs. GHRH alone) and in NS (2,213.8 +/- 212.8 micrograms/l/h; p < 0.005 vs. GHRH alone); however, as the percent potentiating effect of PD was similar in both groups (215 and 247%, respectively) the GH response to GHRH + PD in DS was lower (p < 0.005) than that in NS. The GHRH-induced GH rise was also potentiated by ARG in both DS (2,243 +/- 362.4 micrograms/h; p < 0.001 vs. GHRH alone) and NS (2,764.3 +/- 325.7 micrograms/l/h; p < 0.005 vs. GHRH alone). As the percent potentiating effect of ARG in DS was more marked than in NS (425 vs. 308%, respectively), the GH response to GHRH + ARG became similar in both groups. No sex-related difference was found in the GH response to various stimuli both in DS and NS. In conclusion, these data demonstrate that the potentiating effect of PD but not that of ARG is impaired in adults with DS in whom a reduced somatotrope responsiveness to GHRH is present. These findings indicate that in DS the pituitary GH releasable pool is fully preserved while an impairment of the tuberoinfundibular cholinergic pathways could lead to somatostatinergic hyperactivity and low somatotrope responsiveness to GHRH.
有数据表明,唐氏综合征(DS)患者的胆碱能活性过早受损。另一方面,乙酰胆碱以及精氨酸(ARG)在人体生长激素(GH)分泌的神经控制中起主要刺激作用,可能是通过抑制下丘脑生长抑素的释放来实现的。本研究的目的是验证胆碱酯酶抑制剂吡啶斯的明(PD,口服120毫克)和ARG(静脉注射0.5克/千克)对15名成年DS患者(男/女:8/7;年龄26.5±2.2岁;体重指数,BMI:25.7±1.0千克/平方米)中生长激素释放激素(GHRH)(静脉注射1微克/千克)诱导的GH升高的影响,据报道PD对DS患者GH分泌的增强作用有所降低。将DS患者的结果与15名正常受试者(NS)(男/女:8/7;年龄:30.0±1.3岁;BMI:21.4±0.4千克/平方米)的结果进行比较。DS患者的基础GH和胰岛素样生长因子I(IGF-1)水平(1.8±0.7和206.5±21.0微克/升)与NS患者相似(1.4±0.3和179.4±11.0微克/升)。DS患者单独对GHRH的GH反应(526.5±120.1微克/升/小时)低于(p<0.05)NS患者记录的反应(895.4±153.7微克/升/小时)。在DS患者(1138±184.2微克/升/小时;与单独使用GHRH相比,p<0.02)和NS患者(2213.8±212.8微克/升/小时;与单独使用GHRH相比,p<0.005)中,PD均增强了GHRH诱导的GH升高;然而,由于PD在两组中的增强作用百分比相似(分别为215%和247%),DS患者对GHRH+PD的GH反应低于(p<0.005)NS患者。在DS患者(2243±362.4微克/小时;与单独使用GHRH相比,p<0.001)和NS患者(2764.3±325.7微克/升/小时;与单独使用GHRH相比,p<0.005)中,ARG也增强了GHRH诱导的GH升高。由于ARG在DS患者中的增强作用百分比比NS患者更显著(分别为425%和308%),两组对GHRH+ARG的GH反应变得相似。在DS患者和NS患者中,对各种刺激的GH反应均未发现性别相关差异。总之,这些数据表明,在存在对GHRH的生长激素细胞反应降低的成年DS患者中,PD的增强作用受损,而ARG的增强作用未受损。这些发现表明,在DS患者中,垂体可释放GH的池完全保留,而结节漏斗胆碱能途径的损害可能导致生长抑素能活性亢进和生长激素细胞对GHRH的反应性降低。